Best Pharmaceuticals for Children Act (BPCA) Activities at NICHD
The Best Pharmaceuticals for Children Act (BPCA) Program is a major activity for the Obstetric and Pediatric Pharmacology Branch (OPPB), a component of the Center for Research for Mothers and Children at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
OPPB is responsible for developing and supporting a comprehensive national research and training effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, and childhood using pharmaceuticals that are appropriately tested within their target populations. NICHD activities related to BPCA are intended to improve pediatric drug therapeutics through preclinical and clinical testing that lead to drug labeling change.
Updates |
Hepatic Toxicity Following Treatment for Pediatric Graves Disease Meeting October 28, 2008 6100 Executive Boulevard Rockville, MD |